696 related articles for article (PubMed ID: 33291316)
1. Downregulation of miR-506-3p Facilitates EGFR-TKI Resistance through Induction of Sonic Hedgehog Signaling in Non-Small-Cell Lung Cancer Cell Lines.
Haque I; Kawsar HI; Motes H; Sharma M; Banerjee S; Banerjee SK; Godwin AK; Huang CH
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291316
[TBL] [Abstract][Full Text] [Related]
2. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.
Ahmad A; Maitah MY; Ginnebaugh KR; Li Y; Bao B; Gadgeel SM; Sarkar FH
J Hematol Oncol; 2013 Oct; 6(1):77. PubMed ID: 24199791
[TBL] [Abstract][Full Text] [Related]
4. Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines.
Bai XY; Zhang XC; Yang SQ; An SJ; Chen ZH; Su J; Xie Z; Gou LY; Wu YL
PLoS One; 2016; 11(3):e0149370. PubMed ID: 26943330
[TBL] [Abstract][Full Text] [Related]
5. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
Park KS; Raffeld M; Moon YW; Xi L; Bianco C; Pham T; Lee LC; Mitsudomi T; Yatabe Y; Okamoto I; Subramaniam D; Mok T; Rosell R; Luo J; Salomon DS; Wang Y; Giaccone G
J Clin Invest; 2014 Jul; 124(7):3003-15. PubMed ID: 24911146
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
[TBL] [Abstract][Full Text] [Related]
7.
Hu C; Zhou A; Hu X; Xiang Y; Huang M; Huang J; Yang D; Tang Y
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362025
[TBL] [Abstract][Full Text] [Related]
8. Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features.
Sato H; Shien K; Tomida S; Okayasu K; Suzawa K; Hashida S; Torigoe H; Watanabe M; Yamamoto H; Soh J; Asano H; Tsukuda K; Miyoshi S; Toyooka S
Sci Rep; 2017 Jan; 7():40847. PubMed ID: 28084458
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of miR-641 contributes to erlotinib resistance in non-small-cell lung cancer cells by targeting NF1.
Chen J; Cui JD; Guo XT; Cao X; Li Q
Cancer Med; 2018 Apr; 7(4):1394-1403. PubMed ID: 29493886
[TBL] [Abstract][Full Text] [Related]
10. miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway.
Han J; Zhao F; Zhang J; Zhu H; Ma H; Li X; Peng L; Sun J; Chen Z
Int J Oncol; 2016 May; 48(5):1855-67. PubMed ID: 26936292
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression.
Liao J; Lin J; Lin D; Zou C; Kurata J; Lin R; He Z; Su Y
Sci Rep; 2017 Apr; 7(1):781. PubMed ID: 28396596
[TBL] [Abstract][Full Text] [Related]
12. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
Kitamura K; Seike M; Okano T; Matsuda K; Miyanaga A; Mizutani H; Noro R; Minegishi Y; Kubota K; Gemma A
Mol Cancer Ther; 2014 Feb; 13(2):444-53. PubMed ID: 24258346
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of non-small cell lung cancer to erlotinib is regulated by the Notch/miR-223/
Zhang H; Chen F; He Y; Yi L; Ge C; Shi X; Tang C; Wang D; Wu Y; Nian W
Biosci Rep; 2017 Jun; 37(3):. PubMed ID: 28507201
[TBL] [Abstract][Full Text] [Related]
14. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
[TBL] [Abstract][Full Text] [Related]
15. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
[TBL] [Abstract][Full Text] [Related]
16. Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation.
Wang S; Su X; Bai H; Zhao J; Duan J; An T; Zhuo M; Wang Z; Wu M; Li Z; Zhu J; Wang J
J Hematol Oncol; 2015 Nov; 8():127. PubMed ID: 26563758
[TBL] [Abstract][Full Text] [Related]
17. The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.
Wu F; Li J; Jang C; Wang J; Xiong J
Int J Clin Exp Pathol; 2014; 7(10):6653-61. PubMed ID: 25400744
[TBL] [Abstract][Full Text] [Related]
18. Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC.
Iderzorig T; Kellen J; Osude C; Singh S; Woodman JA; Garcia C; Puri N
Biochem Biophys Res Commun; 2018 Feb; 496(2):770-777. PubMed ID: 29337056
[TBL] [Abstract][Full Text] [Related]
19. Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer.
Zhao J; Guerrero A; Kelnar K; Peltier HJ; Bader AG
Lung Cancer; 2017 Jun; 108():96-102. PubMed ID: 28625657
[TBL] [Abstract][Full Text] [Related]
20. NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers.
Wang X; Yin H; Zhang H; Hu J; Lu H; Li C; Cao M; Yan S; Cai L
Cell Death Dis; 2018 Apr; 9(4):418. PubMed ID: 29549343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
